Rilapladib is a lipoprotein-associated phospholipase A2 inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. It is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. Reference standards of Rilapladib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
